INTRAOSSEOUS ADMINISTRATION OF ANTIBIOTICS

Information

  • Research Project
  • 3489600
  • ApplicationId
    3489600
  • Core Project Number
    R43AI032806
  • Full Project Number
    1R43AI032806-01
  • Serial Number
    32806
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1992 - 32 years ago
  • Project End Date
    2/28/1993 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/1992 - 32 years ago
  • Budget End Date
    2/28/1993 - 31 years ago
  • Fiscal Year
    1992
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/31/1992 - 32 years ago
Organizations

INTRAOSSEOUS ADMINISTRATION OF ANTIBIOTICS

DESCRIPTION: (Adapted from the Applicant's Abstract). Difficulty in obtaining and maintaining intravenous (i.v.) access for repeated administration of medications is a frequent complication encountered during chronic antibiotic therapy for life threatening infections. In a recent study, central venous access lines had to be discontinued in 45% of AIDS patients due to infections and other serious complications. Intraosseous (i.o.) administration, using the Osteoport is proposed as a safer alternative to intravenous administration.This research will evaluate i.o. administration of ceftazidime (CFTZ) through the Osteoport in an animal (goat) model. CFTZ has been chosen as representative of antibiotics which are commonly administered intravenously to AIDS patients. The pharmacokinetics of CFTZ will be compared between i.v. and i.o. administration. Plasma levels of CFTZ will be determined by HPLC on sequential blood samples obtained after administration of a single dose. After repeated i.o. administration of CFTZ, animals will be humanely sacrificed for tissue collection and histology to evaluate local pathology associated with i.o. administration.Demonstration of the suitability of this device and route of administration for CFTZ will direct the commercialization of the Osteoport to replace or supplement intravenous therapies in chronically ill patients. It is estimated that over 50,000 AIDS patients per year could benefit from this technology.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    LIFEQUEST MEDICAL, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN ANTONIO
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    782164681
  • Organization District
    UNITED STATES